This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Shareholder Yield Investor model based on the ...

Fintel reports that on November 12, 2024, Leerink Partners upgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Bristol-Myers Squibb (NYSE:BMY) with a Peer ...

Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the ...

Bristol Myers reports promising preliminary results for its next-gen CAR T therapy CC-97540, showing safety and early efficacy in a Phase 1 study for severe autoimmune diseases.

Wolfe Research has recently initiated Bristol-Myers Squibb Co (BMY) stock to Peer Perform rating, as announced on November 15, 2024, according to Finviz. Earlier, on November 13, 2024, Daiwa ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol-Myers Squibb (BMY – Research Report) ...

Bristol Myers Squibb (BMY) has received a recommendation for approval from an expert panel of the European Medicines Agency ...

On October 31, Bristol-Myers Squibb (NYSE:BMY) released financial results for the third quarter of 2024, which not only beat ...